Drug Profile
Research programme: SIRT-1 activators - RezGen5 Ltd
Alternative Names: RezGen5Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator NeoMedigen
- Developer RezGen5 Ltd
- Class Carotenoids; Nicotinic acids; Polyphenols; Small molecules; Stilbenes; Zinc compounds
- Mechanism of Action Cell cycle inhibitors; DNA repair enzyme stimulants; Free radical scavengers; Glycolysis inhibitors; Immunostimulants; Inflammation mediator inhibitors; Neuron modulators; Nicotinamide adenine dinucleotide modulators; Poly(ADP-ribose) polymerase modulators; SIRT1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Cardiovascular disorders; Neurodegenerative disorders; Obesity; Skin disorders; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Bermuda
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Bermuda
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Bermuda